Background: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk prediction model of FN in patients with hematological cancer at the beginning of a chemotherapy cycle.
background Chemotherapy-induced neutropenia (CIN) is one of the most common serious adverse effects of cancer chemotherapy, often complicated by febrile neutropenia (FN), with an incidence rate per cycle going up to 33% or more in some hematological cancers [1] . In addition to a mortality risk 5% in nonselected patient populations, FN is associated with quality-of-life deterioration, increased treatment costs and may lead to a dose reduction or delay of subsequent chemotherapy regimen, possibly jeopardizing the cure rates and long-term survival. As the prophylactic use of colony-stimulating factors (CSFs) may reduce the risk of FN [2, 3] , it is of great importance to identify, as soon as possible after or even before the start of chemotherapy, patients who might develop FN [4] . Although some risk models have been developed and many factors identified as possible predictors of neutropenic events, they still need to be validated in large-scale prospective studies [4, 5] before their use in practice. Conditional models which predict FN occurrence on the basis of the nadir of the absolute neutrophil count (ANC) after the first cycle can be reliable models in their predictive power [1, [5] [6] [7] but were developed for specific populations and on the basis of the retrospective datasets. Moreover, their practical usefulness is limited as the risk of FN is precisely the highest during the first cycle. In the current clinical practice, the decision to use CSF as prophylaxis is mainly on the basis of the myelosuppressive potential of a chemotherapy regimen [8, 9] . Prophylactic use of CSF is recommended by the American Society of Clinical Oncology [4] and more recently by the European Organisation for Research and Treatment of Cancer [10] when the risk to develop FN is expected to be at least 20%. In some circumstances, the prophylactic use of CSF is also recommended, even if the risk estimate of FN of the chemotherapy regimen does not reach the threshold of 20% [4] . These guidelines provide also a risk estimate of FN for a list of common regimens but no information is available for many other combinations. In many studies, the aggressiveness of the chemotherapy is analyzed in terms of high versus low dose for a particular drug, without integrating the information at the level of a combination. One study presented a list of drugs associated with very frequent neutropenia [11] but it does not help to predict the risk of neutropenia of a given regimen. In a previous study from our group, we computed a classification score for a regimen combining the supposed individual aggressiveness of each drug in the regimen to predict the further duration of neutropenia [12] in patients with fever. However, this was done in patients with solid tumors only; it appeared interesting to extend our work to a population with hematological tumors.
The objective of the present paper is to test this aggressiveness score [12] , adapted and extended for hematological cancers after a review of the specific cytotoxic drugs used and to evaluate its usefulness for prediction of the development of FN.
patients and methods
Patients older than 16 years, with hematological cancer of any type, scheduled to start a new chemotherapy line, were prospectively enrolled and followed at 'Institut Jules Bordet' and 'Cliniques Universitaires St-Luc', in Belgium, from 2001 to 2005. The Institutional Ethical Review Board approved the study and the patients signed an informed consent form before inclusion. Among the 266 enrolled patients, 66 (22.9%), 116 (43.6%) and 89 (33.5%) were followed, respectively, during one cycle, two to four cycles and more than four cycles, adding up to 1053 cycles. Baseline patient's characteristics were noted including sex, age, diagnosis and comorbidities. On day 1 of each cycle, additional variables were collected, such as Karnofsky index, treatment stage, administration of concomitant radiotherapy, detailed chemotherapy regimen, as well as complete blood counts (white blood cells, neutrophil, lymphocyte, monocyte and platelets count, hemoglobinemia, albuminemia and C-reactive protein (CRP) value) and body temperature. Recent history of deep fungal infection (12 months before the beginning of the chemotherapy), mucocutaneous infection or neutropenia (2 months before the beginning of chemotherapy) was also recorded. For hospitalized patients, the temperature was recorded every day and differential blood counts were reassessed every 2 days. The outpatients were advised to consult in case of fever and at this occasion hematological counts were always assessed.
We used as end point the occurrence of FN (i.e. fever ‡38.5°C once or ‡38°C on two occasions in association with an ANC <500 cells/ll with or without infection) in a period of 45 days after the beginning of chemotherapy.
More than 100 chemotherapy regimens were used in the patients' population. They were scored according to the methodology presented by Lalami et al. [12] . In this system (Table 1) , a weight is assigned to each drug according to its expected frequency of severe neutropenia (0 unusual; 1 very rare; 2 rare; 3 frequent; 4 very frequent). This weight was determined using data on the basis of single drug therapy [12] . For some cytotoxic agents, for which myelotoxicity is strongly related to the dose, high doses were defined as adriamycin >90 mg/m 2 Baseline neutropenia, lymphopenia, monocytopenia and thrombocytopenia were defined as a count <1000/ll, 700/ll, 150/ll and 150000/ll, respectively, before the chemotherapy.
For CRP, albumin and hemoglobin, the cut-offs used were, respectively, 10 mg/l, 3 g/dl and 10-12 g/dl.
Other variables were underlying disease in six categories [chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), acute lymphocytic leukemia, lymphoma, myeloma and other], body area, prophylactic administration of CSFs, administration of prophylactic antimicrobial drugs or immunoglobulins, immunosuppressive treatment, concomitant radiotherapy, stem-cell transplantation, presence of an i.v. catheter, first cycle of a chemotherapy line or first cycle following diagnosis, treatment setting (induction, reinduction, consolidation, intensification) and bone marrow involvement (considering it negative for patients with CML or AML in complete remission). 
Oxaliplatin Teniposid A weight (0-4) is assigned to each drug according to its expected frequency of severe neutropenia (0 unusual, 1 very rare, 2 rare, 3 frequent, 4 very frequent). This weight was determined using data on the basis of single drug therapy. a Drugs actually used in the study are given in bold.
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The relationship between our outcome and our covariates was analyzed using the generalized estimating equation (GEE) [13] . GEE is well adapted to our data since it takes into account the repetition of the outcome measurement in the follow-up of several cycles and the covariates by adding a correlation matrix of the outcomes on the same individual in the regression model. This correlation matrix includes an estimation of the correlation coefficients between the different time points within one patient. An accessible description of this method is given in Hanley et al. [14] .
Variables potentially associated with the considered outcome were examined first in univariate GEE analyses. In order to adjust for potential confounding, we also fitted multivariate GEE models using a forward procedure. The covariates were added one by one according to their statistical significance. The criterion for variable removal and entry was set up to 0.10 and 0.05, respectively. The goodness of fit of the models was assessed by a R 2 measure proposed by Zheng [15] : a value of one meaning that the model fit exactly the data (perfect model) and a value of zero meaning that the model is useless.
In all GEE analyses, we used the empirical instead of the model-based standard errors since they are more robust against misspecification of the correlation structure.
All analyses were carried out using SAS software version 9.0 (SAS, Cary, NC) and SPSS 14.0.
results
We excluded 36 cycles for the analysis of FN because of insufficient follow-up duration (<15 days). Most of the 266 patients were <60 years, had no acute primary disease and had no coexisting comorbidities. More than 60% had a lymphoma or an Hodgkin's disease or an AML. Few patients received more than four courses of chemotherapy. The first column of Table 2 presents the characteristics of the 1017 cycles. Many different 25 .1% in myeloma to >80.0% in CML. All together, more than onethird of the cycles (35.3%) were followed by a febrile neutropenic episode. Most of the febrile neutropenic episodes did not exceed 7 days (74.7%) and occurred following the first cycles of a chemotherapy line.
In univariate analysis (columns 2-5 of Table 2 ), the most important potential risk factor for FN during the follow-up of one chemotherapy cycle was the underlying disease (CML and AML) with odds ratios (ORs) of 12.1 and 8.9, respectively, using patients with myeloma as reference. A high chemotherapy score was also strongly associated with FN with an OR of 9. The final model is presented in Table 3 : the aggressiveness of the chemotherapy was one of the major independent predictors of FN with a risk for a patient receiving a very aggressive chemotherapy to develop a FN multiplied by >5 [OR 5.2 (95% CI 3.2-8. 1-2.4)], a bone marrow involvement [OR 2.2 (1.4-3.4) We used the estimates of the regression coefficients obtained in the model to compute a second score to predict FN. The Table 4 shows the weights given to the different items of the score. The maximum computed score is 35 (the higher the score, the higher the probability of FN). A cut-off of 15 for the first cycles and 10 for the other cycles were chosen by optimizing the area under the receiver operating characteristic curve in order to improve the characteristics of the test in the different subgroups. As the test is not useful in AML, its general characteristics are computed without AML. With these cut-offs, the test obtains a general sensitivity of 78.6%, a specificity of 62.3%, a positive predictive value of 42.7%, a negative predictive value of 89.1% and overall misclassification of 33.4% (Table 5 ). With the use of such a score, the administration of CSF would increase only a little (absolute increase of 2%) but better targeted to patients needing it.
conclusions
The incidence of chemotherapy-induced FN can vary from 9% [16] in a nonselected patients population including patients The model is adjusted for prophylactic antimicrobial drug administration and prophylactic administration of CSF. Variables added in the forward procedure: prophylactic administration of IG, prophylactic administration of CSF, other immunosuppressor administration, baseline lymphocyte count <700, baseline monocyte count <150, baseline CRP dosage >10 mg/l, baseline Hb dosage <12, baseline platelets count <150 000, baseline albumin dosage <3 g/dl, baseline neutrophil count <1000/ll, chemotherapy score, graft, bone marrow involvement, prophylactic antiinfectious administration (antibiotic, viral or fungal), underlying disease, chemotherapy score of last cycle, first cycle, very first cycle, body surface <2 m 2 , induction, and reinduction. OR, odds ratio; CI, confidence interval; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphocytic leukemia; Hb, hemoglobin; CSF, colony-stimulating factor.
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with solid tumor to 31% [1] and 48% [17] in studies limited to non-Hodgkin's lymphomas. Our study considered all hematological tumors and found a 35.4% of incidence of FN per chemotherapy cycle. The median neutrophil count at nadir (median 12th day) was 56/ll (range 0-8750).
In the model, eight factors and an interaction were selected for inclusion: chemotherapy score, underlying disease, baseline monocyte count <150/ll, body surface £2 m 2 , use of prophylactic antimicrobial agents, use of prophylactic CSF, bone marrow involvement, stem-cell transplantation and the interaction between the first cycle of a treatment line and the baseline hemoglobinemia.
Although chemotherapy is the most important determinant of the risk of neutropenia [18] , no study except the one published by our group [12] attempted to develop a general scoring system to compare the aggressiveness of the different chemotherapy regimens. Up to now, the aggressiveness of chemotherapy has been studied either in terms of delivered dose intensity or of presence or not of a particularly aggressive drug in the regimen [11] or as a simple comparison of different regimens [19, 20] , making difficult the comparisons between different studies. In our study, we used the same methodology as Lalami to score chemotherapy regimens according to their myelotoxicity with the objective to develop an easy and practical score, assessable before the start of the treatment. Although the actual dose was not considered for other agents, we indirectly included it in the scoring system by taking the average toxicity score of the drugs included in the regimen. Although this agent's classification is not the result of a consensus, this methodology has the merit to be a widely applicable method of classification because it is not specific to particular chemotherapy regimens [12] . In our study, the chemotherapy's score is one of the most important factors in the development of FN. Moreover, this score explains >30% of the variance of FN (R 2 ) and is the highest among the nine factors of the model. The second most important factor in the model is the underlying disease; patients with AML or CML tumor have a risk to develop FN 6 and almost nine times higher, respectively, than the myeloma. We did not find any other study reporting this finding, probably because most of them exclude tumors which could by themselves induce neutropenia, such as AML [11, 12, 16] . The role of monocytopenia (measured on days 6-8) in the development of CIN has been already reported [11, 21] ; interestingly, our model shows that even a baseline monocyte count <150/ll is an independent predictor of FN. An early anemia [19] and in general an early drop of all hematopoietic cell counts after the chemotherapy has been reported in other studies [22, 23] as potential independent predictors of FN. Indeed, we found the baseline hemoglobin level to be also predictor of FN as an interaction with number of cycle. Hemoglobinemia has probably no direct influence on FN, but might be reflecting only bone marrow depletion. As it is described in other studies [6, 7, 12, 18, 19] , the first cycle of a new treatment is strongly associated with FN in our model. In our study, the variable is included as an interaction with hemoglobin levels in a general model that is already valid during the first cycle with an adjustment taking into account this characteristic. Although We used the estimates of the regression coefficients to obtain the weights of the items. The maximum computed score is 35 (the higher the score, the higher the probability of FN). AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphocytic leukemia. older age is usually associated with a higher risk of FN in the literature [18, 20, 22] , we found an opposite relation in our study in univariate analysis. Some other studies found the same relation in hematological [24] and solid tumors [25] [26] [27] [28] . In our sample, this difference between younger and older age can only be explained by the higher proportion of stem-cell transplantation among younger patients. Anyway, age was not selected by the forward procedure in the final model. As found generally in the literature, body surface and bone marrow involvement are associated with FN and were selected in the final model [1, 20, 29] . Although the administration of prophylactic antimicrobial agents is expected to reduce the occurrence of FN, we found an opposite result. It can be easily explained by the fact that the patients are not given these drugs randomly, but only when the risk of neutropenia is higher [4] or on the basis of the medical indication. Some studies found that baseline and early lymphopenia (on day 5) might be associated with FN [11, 16, 30] . We did not find an association between a low baseline lymphocyte count and FN, neither in univariate nor in multivariate analysis.
In the development of this prediction rule, we did not include prophylactic antimicrobial agents administration and prophylactic CSF administration, considering them as simple adjustment variables. A score ‡15 (first cycles) and 10 (further cycles) gives the best results in term of sensitivity, specificity and predictive value and could be used as cut-offs to administer CSF, which would increase a little its use (absolute increase of 2% excepted AML).
reliability and validity of the study In this prospective study, patients with hematological malignancies received a wide variety of cytotoxic agents and regimens with different myelotoxicity, allowing us to test the usefulness of a chemotherapy score. Further, we were able to assess an important number of covariates and confounding factors. The prediction rule developed in this study is mainly on the basis of objective variables, increasing its chance to be reproducible. Moreover, the study is on the basis of a 'not selected population', improving its transportability to other settings.
Some limitations need to be discussed. Some authors [5] argue that good prediction models can only be developed if based on single occurrence in separate patients rather than on repeated occurrences in the same patient. It is true that the therapeutic attitude is different between the first and the subsequent cycles but its confounding potential is reduced by the adjustment realized. Moreover, the advantage of repeated measurements is that the random variability within a patient is lower than between patients leading to a greater power to detect effects.
A weakness of this study is that we were not able to adjust the score according to the actual delivered dose because neither the reason nor the date of the decision of the dose reduction was recorded. Finally, even with the use of different cut-offs for the first cycle and the others, the prediction rule is not applicable in AML.
In spite of some limitations, our results emphasize the need to assess neutropenia risk before chemotherapy initiation, and to identify patients most likely to benefit from pre-emptive hematopoietic growth factor therapy.
As the results have not been validated in a different and independent population, we started a new study to assess the characteristics of our rule in another population before it can be considered to use it in routine.
Further, with such an explained variance, it is clear that we did not identify yet all the independent factors explaining FN and other factors should be investigated in future studies. 
